RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Suzhou’s Innovent and its partner Lilly announced their anti-CD20 biosimilar to rituximab (MabThera/Rituxan) met its primary endpoints in two China clinical trials. The candidate, IBI301, was compared to rituximab in a Phase III trial in patients with diffuse large B-cell lymphoma and also in a pharmacokinetic (PK) study in patients with CD20-positive B-cell lymphoma. The Roche/Genentech drug is the only one in its class available for DLBCL in China; if approved, the Innovent/Lilly biosimilar will offer a less expensive alternative.
Source: China Biotoday
